NASDAQ: KARDKardigan Inc Stock
$22.00
Updated Jun 18, 2026
KARD Price
$22.00
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$16.25
52 Week High
$23.75
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.17
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KARD Overview
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KARD's potential to beat the market
- KARD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KARD
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important KARD news, forecast changes, insider trades & much more!
KARD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KARD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KARD's short-term assets ($298.13M) exceed its short-term liabilities ($31.67M)
Short-term Liabilities Financials
KARD's short-term assets ($298.13M) exceed its long-term liabilities ($19.61M)
Long-term Liabilities Financials
KARD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more KARD due diligence checks available for Premium users.
Valuation
KARD's financial health
Profit margin
Revenue
$0.0
Net Income
-$56.1M
Profit Margin
0%
Assets to liabilities
Assets
$348.2M
Liabilities
$51.3M
Debt to equity
-0.17
KARD's short-term assets ($298.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KARD's short-term assets ($298.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KARD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KARD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$56.8M
Investing
$19.0M
Financing
$10.3M
Kardigan Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.